Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
Not yet recruiting · NCT07831226 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years | Infections, Mosquito-Borne Diseases, Plasmodium falciparum malaria, Plasmodium vivax malaria, malaria, parasitic infectious disease, protozoa infectious disease, vector-borne disease | Not yet recruiting | Phase 1 | 2026-09-25 | NCT07831226 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangzhou Patronus Biotech Co., Ltd. | 7 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nucleus Network Pty Ltd. | Melbourne | Australia | 3 |